Pilot study utilizing Fluorine‐18 fluorodeoxyglucose‐positron emission tomography/computed tomography for glycolytic phenotyping of canine mast cell tumors

Abstract

The goal of this prospective pilot study was to use naturally occurring canine mast cell tumors of various grades and stages as a model for attempting to determine how glucose uptake and markers of biologic behavior are correlated. It was hypothesized that enhanced glucose uptake, as measured by 2-[fluorine-18]fluoro-d-glucose-positron emission tomography/computed tomography (F18 FDG PET-CT), would correlate with histologic grade. Dogs were recruited for this study from a population referred for treatment of cytologically or histologically confirmed mast cell tumors. Patients were staged utilizing standard of care methods (abdominal ultrasound and three view thoracic radiographs), followed by a whole body F18 FDG PET-CT. Results of the F18 FDG PET-CT were analyzed for possible metastasis and standard uptake value maximum (SUV ) of identified lesions. Incisional or excisional biopsies of the accessible mast cell tumors were obtained and histology performed. Results were then analyzed to look for a possible correlation between the grade of mast cell tumors and SUV . A total of nine animals were included in the sample. Findings indicated that there was a correlation between grade of mast cell tumors and SUV as determined by F18 FDG PET-CT (p-value = 0.073, significance ≤ 0.1). Based on the limited power of this study, it is felt that further research to examine the relationship between glucose utilization and biologic aggressiveness in canine mast cell tumors is warranted. This study was unable to show that F18 FDG PET-CT was a better staging tool than standard of care methods.

Prognostic value of fluorine18 flourodeoxyglucose positron emission tomography/computed tomography in dogs with appendicular osteosarcoma

“…The relationship between grade of a disease and prognosis in dogs with OSA is unclear . The more aggressive a tumor, the higher the SUV max in humans and animals . Although we cannot draw conclusions on grade or other proliferative indices such as Ki67 in this study as we lack histology and immunohistochemistry on many of the primary lesions, we postulate that higher SUV max is indicative of a more aggressive form of OSA, leading to a shorter survival time.…”

“…Dogs underwent 18 F‐FDG PET/CT imaging with a Philips Gemini TF Big Bore 16‐slice PET/CT scanner (Philips North America, Andover, Massachusetts) under general anesthesia according to a protocol previously reported . Dogs were administered 18 F‐FDG IV at a dose of 170 μCi/kg.…”

Use of positron emission tomography in medicine and veterinary medicine

“…Badanie umożliwia precyzyjną ocenę stopnia zaawansowania raka przełyku, raków rejonu głowy i szyi, czerniaka i chłoniaków (23,57). Do nielicznych wyjątków, w których badanie PET CT ma ograniczone zastosowanie należą rak prostaty, tarczycy czy proces nowotworowy w obrębie centralnego układu nerwowego (16,24,43).…”

“…Pozytonowa tomografia emisyjna w weterynarii z roku na rok zyskuje coraz większą popularność zarówno w badaniach klinicznych, jak i naukowych (38). Ze względu jednak na wysokie koszty zakupu aparatury, wyposażenia, jak i koszty samego badania, PET nie ma tak powszechnego zastosowania, jak w przypadku innych metod diagnostyki obrazowej (4,16,17). Z danych na 2017 r., znanych jest kilka ośrodków wykorzystujących aparat PET do celów weterynaryjnych w Stanach Zjednoczonych, a koszt ponoszony przez właściciela zwierzęcia wynosi około 1500 USD (18).…”

“…Badanie PET w weterynarii, podobnie jak u ludzi, w szczególności w połączeniu z tomografią komputerową czy rezonansem magnetycznym, pozwala na uzyskanie dokładnych informacji o anatomii i metabolizmie procesu nowotworowego, a także służy różnicowaniu guzów pierwotnych i przerzutów, wykryciu ognisk przerzutów, określeniu stopnia zaawansowania choroby, zaplanowaniu i monitorowaniu przebiegu dalszego leczenia (16,19,29,34,37,39,43,59). Badanie to znalazło uznanie w różnicowaniu zmian nowotworowych i zapalnych (51).…”